Japanese Osteoporosis Drug with Less Frequent Dosing Comes to the US

PRINCETON, N.J. – February 19, 2026 – In a move poised to address a long-standing challenge in American healthcare, MAIA Pharmaceuticals today announced a strategic collaboration with Japan’s Asahi Kasei Pharma to bring a proven osteoporosis therapy, Teribone™ (teriparatide), to the United States. The partnership aims to introduce a treatment option designed to significantly improve patient adherence, a critical factor in combating the debilitating effects of the bone-thinning disease.

Under the agreement, Princeton-based MAIA Pharmaceuticals will spearhead the U.S. development and commercialization of Teribone™, a bone-forming agent that has been successfully used by over one million patients in Japan since its approval there in 2011. The therapy’s key differentiator is its patient-friendly dosing schedule, which could transform how osteoporosis is managed for millions of Americans.

A Silent Epidemic and the Adherence Crisis

Osteoporosis represents a massive and growing public health crisis in the United States. According to the National Osteoporosis Foundation, more than 10 million Americans have been diagnosed with the condition, while another 44 million are at high risk due to low bone mass. The disease is often called a “silent epidemic” because it progresses without symptoms until a bone fractures.

These fragility fractures are the devastating outcome of the disease, leading to chronic pain, loss of mobility, and a documented increase in mortality. The National Institutes of Health has highlighted the significant strain these events place on the healthcare system. Yet, despite the availability of various treatments, real-world patient outcomes remain a significant concern. A primary reason for this gap is poor patient adherence to prescribed therapies.

Many current treatments, particularly the most potent bone-forming agents, require daily self-injections. This daily regimen can be burdensome for patients, many of whom are elderly, leading to inconsistent use or premature discontinuation of therapy. Because patients don't feel sick from osteoporosis itself, the motivation to maintain a difficult daily treatment can wane, compromising its effectiveness and leaving them vulnerable to fractures.

Teribone™: A Proven Therapy with a Patient-Centric Design

Teribone™ was specifically developed by Asahi Kasei Pharma to address this treatment barrier. As an anabolic therapy, it works by stimulating the body to build new, strong bone, rather than simply slowing bone loss like more common anti-resorptive drugs. Its active ingredient, teriparatide, is a well-established synthetic form of human parathyroid hormone.

The crucial innovation lies in its administration. Teribone™ is administered as a subcutaneous injection just once or twice a week. This less frequent schedule is designed to reduce the treatment burden, making it significantly easier for patients to start the therapy and, more importantly, to stay on it for the recommended duration. This approach aligns with how osteoporosis care is delivered in outpatient and retail pharmacy settings, facilitating better long-term management.

“We commend Asahi Kasei Pharma for developing Teribone™ into an important and clinically meaningful osteoporosis therapy,” said Bikram Malik of MAIA Pharmaceuticals in the announcement. “Since its approval in 2011, Teribone™ has been used by more than one million patients in Japan, benefitting from its bone-forming mechanism and practical dosing profile. We are proud to work with Asahi Kasei Pharma to bring this established therapy to patients in the United States.”

Navigating a Competitive US Market

The introduction of Teribone™ into the U.S. will see it enter a competitive but opportunity-rich market. The primary competitor in the teriparatide space has been Eli Lilly’s Forteo, the first FDA-approved anabolic agent, which requires daily injections. While highly effective, Forteo’s market has seen the entry of biosimilars following its patent expiration, increasing price competition. Another daily injectable anabolic agent, Tymlos (abaloparatide), also competes in this space.

Teribone™’s distinct weekly or twice-weekly dosing offers a powerful competitive advantage that is not based on price but on patient quality of life and the potential for superior real-world effectiveness. For physicians and patients frustrated by the challenges of daily injections, a proven alternative that promotes better adherence could be a game-changer. MAIA Pharmaceuticals’ strategy focuses on this patient-centered value proposition, aiming to carve out a significant niche by solving a problem that has plagued osteoporosis care for decades.

MAIA’s role will be to leverage its specialized expertise in the U.S. healthcare system to navigate the complex regulatory and commercial landscape. The company, founded in 2013, specializes in identifying proven medicines with unrealized potential and executing strategies to improve their real-world use and patient adherence.

A Strategic Partnership with a Global Vision

For Asahi Kasei Pharma, this collaboration is a key step in its global expansion strategy. The company has designated its pharmaceuticals business as a top priority under its “Trailblaze Together” medium-term management plan for 2025–2027. Partnering with a U.S.-focused specialist like MAIA allows Asahi Kasei to extend the reach of one of its most successful proprietary therapies into the world’s largest pharmaceutical market.

“We are delighted that this collaboration opens a pathway toward bringing Teribone™ to patients in the United States, in addition to the many patients it has supported in Japan for more than a decade,” stated Yoshikazu Aoki, President of Asahi Kasei Pharma. “We look forward to exploring this opportunity together with MAIA for the benefit of patients in the United States.”

While the announcement marks the official start of the journey, the path to U.S. market approval will require navigating the Food and Drug Administration (FDA) regulatory process. MAIA will lead this effort, which will likely involve clinical trials to confirm the safety and efficacy data for the U.S. population. By focusing on integrating Teribone™ into the care settings where patients are most often treated, MAIA aims to make this effective bone-forming therapy easier for patients to access and maintain, ultimately helping them preserve their mobility and independence.